Avandia Survives Scrutiny From FDA Panel
On Tuesday, the FDA panel voted 22 to 1 to recommend that GlaxoSmithKline's Avandia remain on the market, setting aside widespread outcry from consumers and medical professionals that the medication is unsafe.
While the panel acknowledged that evidence did show an increased risk of heart attack in some Avandia...
Already a subscriber? Click here to login